These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563 [TBL] [Abstract][Full Text] [Related]
10. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)]. Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470 [TBL] [Abstract][Full Text] [Related]
12. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor. Zheng S; Chen LR; Wang HJ; Chen SZ Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649 [TBL] [Abstract][Full Text] [Related]
13. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. Kim TW; Ryu MH; Lee H; Sym SJ; Lee JL; Chang HM; Park YS; Lee KH; Kang WK; Shin DB; Bang YJ; Lee JS; Kang YK Oncologist; 2009 May; 14(5):540-7. PubMed ID: 19411681 [TBL] [Abstract][Full Text] [Related]
14. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
15. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095 [TBL] [Abstract][Full Text] [Related]
16. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352 [TBL] [Abstract][Full Text] [Related]
17. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors]. Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947 [TBL] [Abstract][Full Text] [Related]
19. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs]. Shiba K; Matsumoto T; Hirota S Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796 [TBL] [Abstract][Full Text] [Related]
20. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]